Miromatrix Medical, Inc. (MIRO)

NASDAQ: MIRO · IEX Real-Time Price · USD
4.01 0.06 (1.52%)
Jan 19, 2022 9:38 AM EST - Market open
Market Cap81.22M
Revenue (ttm)40,268
Net Income (ttm)-10.28M
Shares Out20.25M
EPS (ttm)-1.49
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,708
Open3.91
Previous Close3.95
Day's Range4.01 - 4.39
52-Week Range3.71 - 16.52
Betan/a
AnalystsStrong Buy
Price Target22.00 (+448.6%)
Earnings DateNov 15, 2021

About MIRO

Miromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company also develops organ-derived biological products for various applications, such as soft tissue reinforcement and wound care. It uses its perfusion decellularization/recellularization technology to engineer transplantable organs for the people who need them. Miromatrix Medical Inc. has strategical partnerships with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. Miromatrix Medical ...

IndustryBiotechnology
IPO DateJun 24, 2021
Employees36
Stock ExchangeNASDAQ
Ticker SymbolMIRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for MIRO stock is "Strong Buy" and the 12-month stock price forecast is 22.00.

Price Target
$22.00
(448.63% upside)
Analyst Consensus: Strong Buy

News

Miromatrix Submits Pre-IND Request to the FDA for Its External Liver Assist Product to Treat Acute Liver Failure

The request puts Miromatrix on the path for Phase I IND submission and an in-human trial in 2H2022 The request puts Miromatrix on the path for Phase I IND submission and an in-human trial in 2H2022

1 month ago - GlobeNewsWire

Miromatrix Reports Third Quarter 2021 Results

EDEN PRAIRIE, Minn., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to hel...

2 months ago - GlobeNewsWire

Miromatrix to Report Third Quarter 2021 Financial Results

EDEN PRAIRIE, Minn., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to hel...

2 months ago - GlobeNewsWire

Miromatrix Announces the First Successful Transplant of a Bioengineered Whole Organ in a Large Animal

Preclinical study of clinically relevant liver transplants advances the decellularization/recellularization approach, representing a key advancement in new therapies for acute and chronic liver failure ...

3 months ago - GlobeNewsWire

Miromatrix Medical Added to Russell Microcap® Index

EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to he...

3 months ago - GlobeNewsWire

Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and Kidneys

The biotechnology company working to eliminate the organ transplant waitlist outlines expansion of its clinical work, supported by IPO funds and Series C round, led by Baxter, CareDx, and DaVita The bio...

5 months ago - GlobeNewsWire

Miromatrix Medical Announces Closing of Initial Public Offering

EDEN PRAIRIE, Minn., June 28, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (Nasdaq: MIRO) ("Miromatrix"), a life sciences company pioneering a novel technology for bioengineering fully transplantabl...

6 months ago - GlobeNewsWire

Miromatrix Medical Announces Pricing of Upsized Initial Public Offering

EDEN PRAIRIE, Minn., June 24, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (Nasdaq: MIRO) ("Miromatrix"), a life sciences company pioneering a novel technology for bioengineering fully transplantabl...

6 months ago - GlobeNewsWire